Microsoft Word Arakis ceo appointment Final 21aug2017. docx



Yüklə 62,1 Kb.
Pdf görüntüsü
tarix18.07.2018
ölçüsü62,1 Kb.
#56380


Akari Therapeutics Announces Appointment of David Horn Solomon as CEO

NEW YORK and LONDON, August 21, 2017 – Akari Therapeutics (NASDAQ:AKTX

,

is pleased to



announce that Dr David Horn Solomon will be appointed as the company’s new chief executive

officer (CEO), effective August 28, 2017.

“I am very pleased that David will be joining Akari and that we have been successful in attracting a

person of his calibre, with over 20 years of leadership experience in the biotechnology industry,”

said Ray Prudo, M.D., Executive Chairman of Akari. “David has a strong track record of leading Phase

2-stage companies like Akari. most notably, at Zealand Pharma where he led the development of

lixisenatide, which is now commercialized by Sanofi.”

Akari is focused on the development and commercialization of treatments for a range of rare and

orphan autoimmune and inflammatory diseases caused by the dysregulation of complement C5

and/or leukotriene B4 (LTB4).

“I am excited by Akari’s growing and diversified discovery platform and its clinical programs in the

complement mediated diseases, PNH (paroxysmal nocturnal hemoglobinuria) and aHUS (atypical

hemolytic uremic syndrome),” said Solomon. “I believe Akari’s lead compound, Coversin, with its

dual binding sites also has potential in a wide range of other diseases where both the complement

and leukotriene pathways are implicated including a

topic keratoconjunctivitis in the eye

and bullous

pemphigoid in the skin”.

“Akari is building momentum in its research programs and this is a hugely exciting time to join and

help advance its products,” added Solomon who will be based at Akari’s corporate headquarters in

New York City.

About David Horn Solomon

Dr David Horn Solomon was the CEO of Zealand Pharma A/S (NASDAQ:ZEAL) from 2008 to 2015.

Under David’s leadership the company went public on NASDAQ OMX in Copenhagen and its lead

product, Adlixin®, a GLP-1 receptor agonist for the treatment of type II diabetes, was approved in

the US and globally and is now marketed by Sanofi as a monotherapy and in combination with

Lantus as Soliqua®. David was also the CEO of Bionor Pharma ASA (OSL:BIONOR) and until his

appointment at Akari was the Managing Partner of Sund Capital, a Nordic healthcare investment

fund. Dr Solomon studied at Weil Cornell Medicine of Cornell University and its Graduate School of

Medical Science where he received his Ph.D.

About Akari Therapeutics Plc

Akari is a biopharmaceutical company focused on the development and commercialization of

innovative therapeutics to treat orphan autoimmune and inflammatory diseases, in particular those

where the complement system or leukotrienes or both complement and leukotrienes together play

a primary role in disease progression. Akari’s lead drug candidate Coversin is a C5 complement

inhibitor currently being evaluated in paroxysmal nocturnal hemoglobinuria (PNH) and atypical

hemolytic uremic syndrome (aHUS). In addition to its C5 inhibitory activity, Coversin independently

and specifically inhibits leukotriene B4 (LTB4) activity. Akari intends to evaluate Coversin in two

conditions, the skin and eye diseases bullous pemphigoid and atopic keratoconjunctivitis, where the



dual action of Coversin on both C5 and LTB4 may be beneficial. Akari is also developing other tick

derived proteins, including long acting versions.



Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning

of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our

current views about our plans, intentions, expectations, strategies and prospects, which are based

on the information currently available to us and on assumptions we have made. Although we believe

that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by

those forward-looking statements are reasonable, we can give no assurance that the plans,

intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may

differ materially from those described in the forward-looking statements and will be affected by a

variety of risks and factors that are beyond our control. Such risks and uncertainties for our company

include, but are not limited to: needs for additional capital to fund our operations, an inability or

delay in obtaining required regulatory approvals for Coversin and any other product candidates,

which may result in unexpected cost expenditures; risks inherent in drug development in general;

uncertainties in obtaining successful clinical results for Coversin and any other product candidates

and unexpected costs that may result therefrom; failure to realize any value of Coversin and any

other product candidates developed and being developed in light of inherent risks and difficulties

involved in successfully bringing product candidates to market; inability to develop new product

candidates and support existing product candidates; the approval by the FDA and EMA and any

other similar foreign regulatory authorities of other competing or superior products brought to

market; risks resulting from unforeseen side effects; risk that the market for Coversin may not be as

large as expected; inability to obtain, maintain and enforce patents and other intellectual property

rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and

maintain commercial manufacturing arrangements with third party manufacturers or establish

commercial scale manufacturing capabilities; the inability to timely source adequate supply of our

active pharmaceutical ingredients from third party manufacturers on whom the company depends;

our inability to obtain additional capital on acceptable terms, or at all; unexpected cost increases

and pricing pressures; uncertainties of cash flows and inability to meet working capital needs; and

risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange

Commission, including our Annual Report on Form 20-F filed on March 31, 2017. Except as otherwise

noted, these forward-looking statements speak only as of the date of this press release and we

undertake no obligation to update or revise any of these statements to reflect events or

circumstances occurring after this press release. We caution investors not to place considerable

reliance on the forward-looking statements contained in this press release.

For more information

Investor Contact:

The Trout Group

Tricia Truehart

ttruehart@troutgroup.com




+1 646 378 2953

Media Contact:

Mary-Jane Elliott / Sukaina Virji

Consilium Strategic Communications

+44 (0)20 3709 5700



Akari@consilium-comms.com

Yüklə 62,1 Kb.

Dostları ilə paylaş:




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©genderi.org 2024
rəhbərliyinə müraciət

    Ana səhifə